{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Env+2-3&page=2", "query": { "intervention": "Env 2-3", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 10, "total_pages": 1, "next_page_url": null, "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Env+2-3&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-09-26T17:42:36.610Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT01260727", "title": "Evaluating the Safety of and Immune Response to an HIV Vaccine Followed by Booster, Administered by Two Devices, in HIV-Uninfected Adults", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "HIV Infections" ], "interventions": [ { "name": "PENNVAX-G DNA Vaccine", "type": "BIOLOGICAL" }, { "name": "MVA-CMDR Vaccine", "type": "BIOLOGICAL" }, { "name": "Placebo PENNVAX-G Vaccine", "type": "BIOLOGICAL" }, { "name": "Placebo MVA-CMDR Vaccine", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "49 Years", "sex": "ALL", "summary": "18 Years to 49 Years" }, "enrollment_count": 92, "start_date": "2010-02", "completion_date": "2015-06", "has_results": false, "last_update_posted_date": "2021-11-01", "last_synced_at": "2026-09-26T17:42:36.610Z", "location_count": 1, "location_summary": "Rockville, Maryland", "locations": [ { "city": "Rockville", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT01260727" }, { "nct_id": "NCT03837756", "title": "Combining TLR9 Agonist With bNAbs for Reservoir Reduction and Immunological Control of HIV", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "HIV-1-infection" ], "interventions": [ { "name": "Saline", "type": "DRUG" }, { "name": "Lefitolimod", "type": "DRUG" }, { "name": "3BNC117 and 10-1074", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Aarhus", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 47, "start_date": "2019-05-06", "completion_date": "2023-05-01", "has_results": false, "last_update_posted_date": "2023-05-23", "last_synced_at": "2026-09-26T17:42:36.610Z", "location_count": 1, "location_summary": "Salt Lake City, Utah", "locations": [ { "city": "Salt Lake City", "state": "Utah" } ], "official_url": "https://clinicaltrials.gov/study/NCT03837756" }, { "nct_id": "NCT02296541", "title": "Evaluating the Safety and Immune Response to Three Different DNA HIV Vaccines Administered With a MVA-CMDR Boost Vaccine in Healthy, HIV-Uninfected Adults", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "HIV Infections" ], "interventions": [ { "name": "DNA Nat-B env", "type": "BIOLOGICAL" }, { "name": "DNA CON-S env", "type": "BIOLOGICAL" }, { "name": "DNA Mosaic env", "type": "BIOLOGICAL" }, { "name": "MVA-CMDR", "type": "BIOLOGICAL" }, { "name": "Placebo for DNA Nat-B env", "type": "BIOLOGICAL" }, { "name": "Placebo for DNA CON-S env", "type": "BIOLOGICAL" }, { "name": "Placebo for DNA Mosaic env", "type": "BIOLOGICAL" }, { "name": "Placebo for MVA-CMDR", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "50 Years", "sex": "ALL", "summary": "18 Years to 50 Years" }, "enrollment_count": 105, "start_date": "2014-12", "completion_date": "2020-07-06", "has_results": false, "last_update_posted_date": "2023-04-24", "last_synced_at": "2026-09-26T17:42:36.610Z", "location_count": 6, "location_summary": "Birmingham, Alabama • San Francisco, California • Decatur, Georgia + 2 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "San Francisco", "state": "California" }, { "city": "Decatur", "state": "Georgia" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT02296541" }, { "nct_id": "NCT05828095", "title": "A Clinical Trial to Evaluate the Safety and Immunogenicity of Synthetic DNAs Encoding a Native-like HIV Env Trimer and Interleukin-12 (INO-6160), Alone or in a Prime-boost Regimen With 3M-052-AF + Alum Adjuvanted VRC HIV Env Trimer 4571 in Adult Participants Without HIV", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "HIV-1-infection" ], "interventions": [ { "name": "INO-6160, 2 mg", "type": "BIOLOGICAL" }, { "name": "Trimer-4571 / 100 mcg 3M-052-AF (5 mcg) + Alum (500 mcg)", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 20, "start_date": "2023-04-05", "completion_date": "2025-01-23", "has_results": true, "last_update_posted_date": "2025-09-02", "last_synced_at": "2026-09-26T17:42:36.610Z", "location_count": 3, "location_summary": "New York, New York • Philadelphia, Pennsylvania • Nashville, Tennessee", "locations": [ { "city": "New York", "state": "New York" }, { "city": "Philadelphia", "state": "Pennsylvania" }, { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT05828095" }, { "nct_id": "NCT00000958", "title": "A Placebo-Controlled, Phase I, Pilot Clinical Trial to Evaluate the Safety and Immunogenicity of ENV 2-3, a Yeast-Derived Recombinant Envelope Protein of Human Immunodeficiency Virus-1, in Combination With MTP-PE/MF59 in Individuals With HIV Infection (Placebo Patients Receive MF59 Emulsion Only)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "HIV Infections" ], "interventions": [ { "name": "MTP-PE/MF59", "type": "BIOLOGICAL" }, { "name": "Env 2-3", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "50 Years", "sex": "ALL", "summary": "18 Years to 50 Years" }, "enrollment_count": 8, "start_date": null, "completion_date": "1995-09", "has_results": false, "last_update_posted_date": "2021-11-04", "last_synced_at": "2026-09-26T17:42:36.610Z", "location_count": 1, "location_summary": "Rochester, New York", "locations": [ { "city": "Rochester", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00000958" }, { "nct_id": "NCT02788045", "title": "Safety, Tolerability and Immunogenicity Study of Different Vaccine Regimens of Trivalent Ad26.Mos.HIV or Tetravalent Ad26.Mos4.HIV Along With Clade C Glycoprotein (gp)140 in Healthy Human Immunodeficiency Virus (HIV)-Uninfected Adults", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Healthy" ], "interventions": [ { "name": "Ad26.Mos.HIV", "type": "BIOLOGICAL" }, { "name": "Ad26.Mos4.HIV", "type": "BIOLOGICAL" }, { "name": "Clade C gp140", "type": "BIOLOGICAL" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Janssen Vaccines & Prevention B.V.", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "50 Years", "sex": "ALL", "summary": "18 Years to 50 Years" }, "enrollment_count": 201, "start_date": "2016-07-08", "completion_date": "2022-04-25", "has_results": true, "last_update_posted_date": "2025-05-25", "last_synced_at": "2026-09-26T17:42:36.610Z", "location_count": 9, "location_summary": "Birmingham, Alabama • San Francisco, California • Decatur, Georgia + 6 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "San Francisco", "state": "California" }, { "city": "Decatur", "state": "Georgia" }, { "city": "Silver Spring", "state": "Maryland" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT02788045" }, { "nct_id": "NCT03606213", "title": "Therapeutic Vaccination in Treated HIV Disease", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "HIV-1-infection" ], "interventions": [ { "name": "PENNVAX-GP", "type": "BIOLOGICAL" }, { "name": "INO-6145", "type": "BIOLOGICAL" }, { "name": "INO-9012", "type": "BIOLOGICAL" }, { "name": "CELLECTRA® 2000", "type": "DEVICE" } ], "intervention_types": [ "BIOLOGICAL", "DEVICE" ], "sponsor": "Steven Deeks", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 56, "start_date": "2018-08-01", "completion_date": "2021-05-17", "has_results": true, "last_update_posted_date": "2023-05-31", "last_synced_at": "2026-09-26T17:42:36.610Z", "location_count": 2, "location_summary": "Los Angeles, California • San Francisco, California", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03606213" }, { "nct_id": "NCT07675629", "title": "Evaluating the Safety and Immunogenicity of Polyvalent DNA and Recombinant gp120 Protein HIV Vaccine (PDPHV) in Healthy, HIV-uninfected Adults", "overall_status": "NOT_YET_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "HIV Prevention" ], "interventions": [ { "name": "PDPHV Plasmid DNA Vaccines (env (A, B, C, A/E)/gag (C))", "type": "BIOLOGICAL" }, { "name": "PDPHV Recombinant Protein Vaccines (gp120 (A, B, C, A/E))", "type": "BIOLOGICAL" }, { "name": "Alhydrogel adjuvant", "type": "BIOLOGICAL" }, { "name": "GLA-SE adjuvant", "type": "BIOLOGICAL" }, { "name": "Placebo for DNA Vaccines, Protein Vaccines and Adjuvants", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Worcester HIV Vaccine", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 126, "start_date": "2026-09-01", "completion_date": "2029-08", "has_results": false, "last_update_posted_date": "2026-06-30", "last_synced_at": "2026-09-26T17:42:36.610Z", "location_count": 1, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT07675629" }, { "nct_id": "NCT06267872", "title": "A Clinical Trial in Adult Participants Without HIV and in Overall Good Health to Evaluate the Safety and Immunogenicity of CD4BS CH505M5 Pr-NP1 Followed by CH505 TF chTrimer Boost Both Adjuvanted With Either Lipid Nanoparticles (LNPs) or 3M-052-AF + Alum", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "HIV" ], "interventions": [ { "name": "CD4BS CH505M5 Pr-NP1", "type": "BIOLOGICAL" }, { "name": "CH505TF chTrimer", "type": "BIOLOGICAL" }, { "name": "3M-052-AF (labeled as AP 60-702)", "type": "BIOLOGICAL" }, { "name": "Aluminum Hydroxide Suspension (Alum)", "type": "BIOLOGICAL" }, { "name": "ACU-026-001-1 (labeled as empty LNP)", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 0, "start_date": "2024-10-07", "completion_date": "2026-09-12", "has_results": false, "last_update_posted_date": "2025-03-26", "last_synced_at": "2026-09-26T17:42:36.610Z", "location_count": 3, "location_summary": "Birmingham, Alabama • Atlanta, Georgia • Nashville, Tennessee", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT06267872" }, { "nct_id": "NCT00000972", "title": "A Phase I Clinical Trial to Evaluate: Part A. The Safety of MTP-PE/MF59 Adjuvant Emulsion. Part B. The Safety and Immunogenicity of Env 2-3, a Yeast Derived Recombinant Envelope Protein of Human Immunodeficiency Virus-1, in Combination With MTP-PE/MF59", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "HIV Infections", "HIV Seronegativity" ], "interventions": [ { "name": "MTP-PE/MF59", "type": "BIOLOGICAL" }, { "name": "Env 2-3", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "50 Years", "sex": "ALL", "summary": "18 Years to 50 Years" }, "enrollment_count": 64, "start_date": null, "completion_date": "1992-04", "has_results": false, "last_update_posted_date": "2021-11-04", "last_synced_at": "2026-09-26T17:42:36.610Z", "location_count": 3, "location_summary": "Rochester, New York • Nashville, Tennessee • Seattle, Washington", "locations": [ { "city": "Rochester", "state": "New York" }, { "city": "Nashville", "state": "Tennessee" }, { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT00000972" } ] }